Drugs & Targets Onureg oral therapy receives FDA approval for continued treatment for adults in first remission with AML September 04, 2020Vol.46 No.33
Drugs & Targets Kyprolis and Darzalex receives FDA approval for combination therapy for multiple myeloma September 04, 2020Vol.46 No.33
Drugs & Targets Blenrep receives FDA approval in relapsed or refractory multiple myeloma September 04, 2020Vol.46 No.33
Drugs & Targets Guardant360 CDx assay receives FDA approval as first liquid biopsy NGS companion diagnostic test September 04, 2020Vol.46 No.33
Drugs & Targets ClonoSEQ assay receives expanded FDA clearance to assess MRD in CLL September 04, 2020Vol.46 No.33
Drugs & Targets Melflufen receives FDA Priority Review for triple-class refractory multiple myeloma September 04, 2020Vol.46 No.33
Drugs & Targets FDA to evaluate cancer therapies in patients with brain metastases September 04, 2020Vol.46 No.33
Drugs & Targets FDA updates analysis of medical device reports of breast implant illness and breast implant-associated lymphoma September 04, 2020Vol.46 No.33
Drugs & Targets Dragonfly Therapeutics, BMS agree to exclusive global license for IL-12 investigational immunotherapy program September 04, 2020Vol.46 No.33
Drugs & Targets Thermo Fisher Scientific, Hengrui Therapeutics to develop companion diagnostic in NSCLC indication September 04, 2020Vol.46 No.33
